Influences of warming kidney prescription on antiviral therapeutic efficacy and creatine kinase in telbivudine-treated HBeAg-positive chronic hepatitis B patients.
10.3760/cma.j.issn.1007-3418.2012.02.005
- Author:
Xiao-Yu HU
1
;
Yang ZHANG
;
Guang-Wei LIU
;
Hong-Ming NIE
;
Xin-Jiang FAN
;
Sen ZHONG
Author Information
1. Department of Infectious Diseases, Affiliated Hospital, Chengdu University of Traditional Chinese Medicine, Chengdu, China. meddmail@yahoo.com.cn
- Publication Type:Journal Article
- MeSH:
Adult;
Antiviral Agents;
therapeutic use;
Creatine Kinase;
blood;
Female;
Hepatitis B, Chronic;
blood;
drug therapy;
Humans;
Male;
Middle Aged;
Nucleosides;
therapeutic use;
Phytotherapy;
Pyrimidinones;
therapeutic use;
Thymidine;
analogs & derivatives
- From:
Chinese Journal of Hepatology
2012;20(2):93-97
- CountryChina
- Language:Chinese
-
Abstract:
To study the influences of warming kidney prescription on antiviral therapeutic efficacy and creatine kinase (CK) level in telbivudine-treated HBeAg-positive chronic hepatitis B patients with kidney yang deficiency syndrome. Ninety-six cases were enrolled and randomly divided into two groups (n=48 each): warming kidney prescription treatment or control. Both groups were treated for 52 weeks with telbivudine monotherapy, but the treatment group received additional treatment with the warming kidney prescription. Traditional Chinese medicine (TCM) syndrome score, biochemical response, virological response, serological response, CK level, and adverse reactions were recorded for each group in order to perform comparative analysis of the warming kidney prescription's effects. A total of 84 patients, including 43 cases in the treatment group, completed the study. The warming kidney prescription led to significantly improved total clinical syndrome efficacy, TCM syndrome score, biochemical response, virological response, and HBeAg serological responses, as evidenced by changes for each parameter observed in the treatment group versus the control group (respectively, 88.37% vs. 63.41%, 4.97+/-1.88 vs. 10.13+/-3.72, 95.35% vs. 75.61%, 81.40% vs. 56.10%, 48.84% vs. 26.83% (all, P less than 0.05)). No patient in either group experienced primary treatment failure. Seven cases, all from the control group, experienced virological breakthrough. Elevated CK was observed in both the treatment and control groups, but significantly more patients in the control group experienced this adverse reaction (respectively, 73.17% vs. 44.19%; P less than 0.01). The warming kidney prescription can increase telbivudine antiviral therapeutic efficacy and decrease the telbivudine-induced increase in creatine kinase in HbeAg-positive chronic hepatitis B patients with kidney yang deficiency syndrome.
